State of Alaska, Department of Revenue - NEKTAR THERAPEUTICS ownership

NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 137 filers reported holding NEKTAR THERAPEUTICS in Q3 2023. The put-call ratio across all filers is 5.78 and the average weighting 0.0%.

Quarter-by-quarter ownership
State of Alaska, Department of Revenue ownership history of NEKTAR THERAPEUTICS
ValueSharesWeighting
Q1 2023$90
-69.5%
128,708
-1.7%
0.00%
-75.0%
Q4 2022$295
-99.9%
130,878
+0.9%
0.00%
-33.3%
Q3 2022$415,000
-22.4%
129,745
-7.9%
0.01%
-14.3%
Q2 2022$535,000
-22.6%
140,915
+9.8%
0.01%0.0%
Q1 2022$691,000
-60.8%
128,380
-1.8%
0.01%
-58.8%
Q4 2021$1,765,000
+242.1%
130,670
+354.2%
0.02%
+240.0%
Q3 2021$516,000
+7.1%
28,772
+2.2%
0.01%0.0%
Q2 2021$482,000
-15.4%
28,145
-1.2%
0.01%
-16.7%
Q1 2021$570,000
+15.4%
28,501
-2.1%
0.01%0.0%
Q4 2020$494,000
-2.4%
29,103
-4.7%
0.01%0.0%
Q3 2020$506,000
-31.0%
30,523
-3.6%
0.01%
-33.3%
Q2 2020$733,000
+35.7%
31,678
+4.7%
0.01%0.0%
Q1 2020$540,000
-13.5%
30,270
+4.6%
0.01%
+12.5%
Q4 2019$624,000
+10.1%
28,926
-7.2%
0.01%0.0%
Q3 2019$567,000
-61.5%
31,178
-24.8%
0.01%
-68.0%
Q2 2019$1,473,000
-12.4%
41,436
-17.3%
0.02%
-16.7%
Q1 2019$1,682,000
+5.9%
50,112
+3.6%
0.03%
-3.2%
Q4 2018$1,589,000
-42.9%
48,377
+6.0%
0.03%
-34.0%
Q3 2018$2,781,000
+32.7%
45,646
+6.3%
0.05%
+27.0%
Q2 2018$2,095,000
+189.4%
42,960
+529.9%
0.04%
+146.7%
Q1 2018$724,000
-61.3%
6,820
-78.3%
0.02%
-66.7%
Q4 2017$1,873,000
+152.1%
31,375
+1.3%
0.04%
+18.4%
Q3 2017$743,000
+24.2%
30,985
+1.2%
0.04%
-7.3%
Q2 2017$598,000
+49.5%
30,625
+79.6%
0.04%
+41.4%
Q1 2017$400,000
+97.0%
17,050
+2.8%
0.03%
+52.6%
Q4 2016$203,00016,5900.02%
Other shareholders
NEKTAR THERAPEUTICS shareholders Q3 2023
NameSharesValueWeighting ↓
Rhenman & Partners Asset Management AB 508,000$6,132,0001.80%
Bodri Capital Management, LLC 250,000$3,018,0001.46%
Granahan Investment Management 3,442,980$41,557,0001.28%
TIRSCHWELL & LOEWY INC 603,441$7,284,0001.22%
NEA Management Company, LLC 1,825,600$22,035,0001.12%
Cormorant Asset Management, LP 450,000$5,432,0001.12%
HARVEY CAPITAL MANAGEMENT INC 221,750$2,676,0001.05%
Cheyne Capital Management (UK) LLP 229,577$2,772,0000.99%
Artal Group S.A. 1,650,000$19,916,0000.73%
FIC CAPITAL INC 147,293$1,778,0000.71%
View complete list of NEKTAR THERAPEUTICS shareholders